


0120 #4

PATENT
Attorney Docket No. 02481.1742



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of)
E. UHLMANN et al.)
Application No.: 09/835,370) Group Art Unit: Not Yet Assigned
Filed: April 17, 2001) Examiner: Not Yet Assigned
For: POLYAMIDE NUCLEIC ACID)
DERIVATIVES AND AGENTS)
AND PROCESSES FOR)
PREPARING THEM)

Assistant Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)


Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents listed on the attached Form PTO-1449. This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced application.

Copies of the listed documents are attached.

Applicants respectfully request that the Examiner consider the documents listed on the attached Form PTO-1449 and indicate that they were considered by making appropriate notations on the attached Form PTO-1449.

Additionally, Applicants would like to bring to the Examiner's attention the following co-pending U.S. patent application, which relates to similar subject matter:



U.S. Patent Application No. 09/835,371 filed April 17, 2001,
entitled: POLYAMIDE NUCLEIC ACID DERIVATIVES AND
AGENTS AND PROCESSES FOR PREPARING THEM.

A copy of this co-pending application is attached.


This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each, any, or all of the listed documents are material or constitute prior art. If the Examiner applies any of the documents as prior art against any claim in the application and Applicants determine that the cited documents do not constitute prior art under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the claimed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

By: 

Matthew T. Latimer
Reg. No. 44,024
(202) 408-4495
matthew.latimer@finnegan.com

Date: October 26, 2001

LAW OFFICES
FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, DC 20005
202-408-4000